Answers are grounded in this paper and cite their sources.
Chronic kidney disease (CKD), a heterogeneous disorder with limited therapeutic options, is often complicated by drug-induced nephrotoxicity from aminoglycosides, such as gentamicin (GM). Nintedanib (NTD), a tyrosine kinase inhibitor with antifibrotic and anti-inflammatory properties, holds promise but is limited by poor solubility, low bioavailability, and potential systemic toxicity. To overcome these challenges, a nintedanib nanosuspension polymer (NTD-PNP) was developed using polycaprolactone (PCL) to improve solubility, control drug release, and maximize oral bioavailability. Physicochemical classification confirmed spherical, smooth-surfaced nanoparticles with particle sizes of 106.5-154.7 nm, ζ-potential of -1.39 to +8.86 mV, polydispersity index (PDI) of 0.139-0.384, entrapment efficiency of 28.92-70.92%, and drug loading of 19.94-47.28%. Compared with the free drug, NTD-PNPs displayed superior solubility and prolonged release kinetics. The therapeutic efficacy of NTD-PNPs was evaluated for 28 days in a gentamicin-induced CKD rat model (100 mg/kg, 21 days). Treatment with NTD-PNPs significantly reduced blood urea nitrogen and creatinine levels, indicating improved renal function. Immunohistochemical analysis further revealed downregulation of fibronectin, α-SMA, Smad3, and collagen III expression, and histopathology showed a reduction in tubular degeneration, extracellular matrix accumulation, and fibrosis. Collectively, these findings demonstrate that NTD-PNPs enhance the therapeutic index of nintedanib, offering a promising sustained-release nano formulation to mitigate CKD progression.
No takes yet. Share an insight, caveat, or question.
Prajapati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: